Table 2.

Performance measures following D₁ and D₂ blockade and stimulation during probabilistic reversal learning, probabilistic discounting, and reward magnitude discrimination.

	Saline	Low dose	High dose
Probabilistic reversal
D1 antagonist (SCH 23390)
Response latency	0.79 ± 0.1	0.73 ± 0.1	0.73 ± 0.1
Trial omissions	3.1 ± 2	1.8 ± 1	3.3 ± 2
Locomotion	1398 ± 168	1421 ± 116	1210 ± 175
D2 antagonist (eticlopride)
Response latency	0.67 ± 0.1	0.73 ± 0.1	0.72 ± 0.1
Trial omissions	4.2 ± 3	2.4 ± 2	5.3 ± 4
Locomotion	1634 ± 169	1711 ± 124	1659 ± 211
D1 agonist (SKF 81297)
Response latency	0.70 ± 0.1	0.60 ± 0.1	0.61 ± 0.1
Trial omissions	7.8 ± 6	1.9 ± 1	1.3 ± 1
Locomotion	1594 ± 191	1434 ± 239	1556 ± 202
D2 agonist (quinpirole)
Response latency	0.84 ± 0.1	1.04 ± 0.2	1.34 ± 0.3
Trial omissions	9.4 ± 5	6.0 ± 2	34.8 ± 18*
Locomotion	1423 ± 191	1179 ± 184	1228 ± 159
Probabilistic discounting
D1 antagonist (SCH 23390)
Response latency	0.71 ± 0.1	0.67 ± 0.1	0.92 ± 0.1*
Trial omissions	3.8 ± 2	2.7 ± 1	6.2 ± 3
Locomotion	1698 ± 241	1531 ± 251	1453 ± 241
D2 antagonist (eticlopride)
Response latency	0.81 ± 0.1	0.75 ± 0.1	0.95 ± 0.2
Trial omissions	5.5 ± 3	2.1 ± 1	4.2 ± 2
Locomotion	1409 ± 164	1454 ± 150	1374 ± 158
D1 agonist (SKF 81297)
Response latency	1.08 ± 0.1	1.14 ± 0.1	1.02 ± 0.1
Trial omissions	3.6 ± 2	4.9 ± 2	3.8 ± 1
Locomotion	1441 ± 202	1101 ± 108	1399 ± 141
D2 agonist (quinpirole)
Response latency	0.76 ± 0.1	0.91 ± 0.1	0.95 ± 0.1
Trial omissions	1.8 ± 1	1.4 ± 1	4.1 ± 2*
Locomotion	1482 ± 221	1332 ± 117	1034 ± 107*
Reward magnitude
D1 antagonist (SCH 23390)
Response latency	0.79 ± 0.1	0.75 ± 0.1	0.77 ± 0.1
Trial omissions	0 ± 0	0 ± 0	0 ± 0
Locomotion	990 ± 112	1081 ± 107	1135 ± 92
D2 agonist (quinpirole)
Response latency	1.41 ± 0.3	1.77 ± 0.3	2.70 ± 0.5*
Trial omissions	1.6 ± 1	6.5 ± 3	17.8 ± 4*
Locomotion	678 ± 131	554 ± 109	674 ± 331

Latencies are measured in s, and locomotion is indexed by photobeam breaks. Values displayed are mean ± SEM.

*p < 0.05 compared to saline.